Business Context and Reporting Period
The source text is an unaudited Form 10-Q for Ambac Financial Group, Inc., not Octave Specialty Group Inc. It covers the three months ended March 31, 2017, with comparative results for the three months ended March 31, 2016. Ambac operates financial guarantee and financial services businesses, both substantially in runoff; it has not written new financial guarantee policies since 2008.
The company disclosed substantial doubt about its ability to continue as a going concern, although the financial statements were prepared on a going-concern basis without related adjustments.
Key Financial Metrics
| Metric | Q1 2017 | Q1 2016 | Change |
|---|---|---|---|
| Total revenue | $126.2 million | $16.9 million | Higher, primarily from VIE activity and investment income |
| Net premiums earned | $47.6 million | $52.8 million | Down $5.2 million |
| Net investment income | $81.6 million | $60.8 million | Up $20.7 million |
| Losses and loss expenses | $135.0 million expense | $105.3 million benefit | Adverse $240.3 million swing |
| Pre-tax income (loss) | $(105.9) million | $12.9 million | Declined $118.7 million |
| Net income (loss) | $(125.4) million | $9.4 million | Declined $134.9 million |
| Basic and diluted EPS | $(2.77) | $0.21 | Declined $2.98 |
| Net margin | Approximately (99%) | Approximately 56% | Not meaningful because of large loss-reserve effects |
| Operating cash flow | $(2.6) million | $828.1 million | Lower by $830.7 million |
| Net cash flow | $27.7 million | $(6.6) million | Improved by $34.3 million |
At March 31, 2017, total assets were $22.8 billion, total liabilities were $20.9 billion and total stockholders’ equity was $1.9 billion. Ambac Financial Group stockholders’ equity was $1.6 billion, or $35.92 per share. Non-GAAP adjusted book value was $1.2 billion, or $27.09 per share.
Cash and cash equivalents were $118.8 million, compared with $91.0 million at December 31, 2016. Management identified approximately $156 million of cash and liquid investments at the parent level. Consolidated investments totaled $6.3 billion.
Long-term debt was $1.0 billion excluding variable-interest-entity debt. Consolidated variable-interest-entity long-term debt was $11.6 billion. Accrued interest payable was $396.9 million, including significant accrued interest on surplus notes and junior surplus notes.
Material Changes Versus the Prior Comparable Period
- Results shifted from a $9.4 million profit to a $125.4 million net loss, principally because Q1 2017 included $135.0 million of loss and loss expenses versus a $105.3 million benefit in Q1 2016.
- Domestic public finance losses were $169.2 million, driven primarily by adverse developments in Puerto Rico. The company recorded a $169.4 million expense associated with its public finance insured portfolio.
- The Ballantyne litigation settlement produced an approximately $73.3 million net benefit in Q1 2017 through reduced loss reserves; the settlement did not generate a direct cash payment to Ambac UK.
- Net investment income increased by $20.7 million, while interest-rate derivative losses improved substantially to $1.5 million from $83.4 million.
- Income from variable-interest-entity activities improved to $3.7 million from a $27.2 million loss.
- Total insured net par exposure declined to $74.7 billion from $79.3 billion, primarily through maturities, amortization, calls, refundings and refinancings. Below-investment-grade exposure declined to $15.8 billion from $16.8 billion.
- Loss and loss expense reserves increased to $4.5 billion from $4.4 billion; net reserves after subrogation recoverables and before reinsurance increased to $3.8 billion from $3.7 billion.
- The last remaining investment agreement matured in March 2017, eliminating $82.4 million of investment-agreement liabilities and contributing to financing cash outflows.
- Ambac paid cash and exchanged insured bonds to extinguish surplus-note obligations and recognized a $2.7 million gain on debt extinguishment.
Outlook, Risks, Contingencies and Unusual Items
- Segregated Account rehabilitation: Ambac Assurance remained in rehabilitation proceedings. Management was pursuing possible asset monetizations, liability exchanges, commutations and other transactions, but no agreement had been reached. OCI and the Rehabilitation Court retain significant approval and control rights.
- Going-concern risk: Management stated that uncertainty over the rehabilitator’s oversight and Ambac Assurance’s ability to deliver value creates substantial doubt about the company’s ability to continue as a going concern.
- Puerto Rico: Ambac had approximately $2.1 billion of Puerto Rico net par exposure. The Commonwealth and COFINA subsequently entered Title III proceedings under PROMESA in May 2017. The company warned that restructuring outcomes, litigation and payment discounts could cause losses materially exceeding current reserves.
- Reserve sensitivity: Possible additional loss reserves were estimated at approximately $1.6 billion for public finance credits, $2.0 billion for RMBS including loss of estimated representation-and-warranty recoveries, $200 million for student loans and approximately $300 million for other credits including Ambac UK. These are stress estimates, not forecasts.
- Liquidity: Parent liquidity depends primarily on cash, liquid investments, expense-sharing arrangements and potential tax tolling payments. Dividend payments from Ambac Assurance were considered highly unlikely for the foreseeable future.
- Regulatory capital: Ambac Assurance statutory policyholder surplus was $944.8 million, above the $100 million minimum surplus amount. Ambac UK, however, reported a Solvency II capital deficiency of approximately £344.6 million after the Ballantyne settlement.
- Litigation and recoveries: The company was involved in numerous Puerto Rico, RMBS, military housing and other legal proceedings. Recoverability of approximately $1.9 billion of recorded representation-and-warranty subrogation recoveries remains uncertain.
- Market and valuation risk: Results remain sensitive to interest rates, credit spreads, foreign exchange, fair-value models, collateral requirements, investment performance and changes in Ambac’s perceived creditworthiness.
- No formal earnings or financial guidance was provided in the filing. Management’s outlook centers on runoff, loss mitigation, recoveries, liability management and efforts to exit rehabilitation.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for Ambac Financial Group, Inc., while the request metadata names Octave Specialty Group Inc.
- Review the terms, timing and required approvals for any proposed Segregated Account exit or liability restructuring transaction.
- Monitor Puerto Rico and COFINA Title III proceedings, payment recoveries, litigation stays and their effect on reserves and liquidity.
- Reconcile reported reserves with the company’s disclosed stress sensitivities, particularly the potential loss of RMBS representation-and-warranty recoveries.
- Assess parent liquidity, expected tax tolling payments, restrictions on Ambac Assurance dividends and upcoming debt or interest obligations.
- Verify Ambac UK’s Solvency II capital remediation plan and the effect of the Ballantyne settlement.
- Evaluate the reliability of Level 3 fair values, estimated subrogation recoveries and other management judgments underlying book value and adjusted book value.